Alteogen is a bioventure company established in 2008, focusing on the development of biopharmaceuticals, biobetters, and biosimilars. The company possesses innovative platform technologies, including human-derived hyaluronidase, which have led to successful technology transfer agreements with global pharmaceutical companies. Since its listing on the KOSDAQ in 2014, Alteogen has shown rapid growth and currently ranks as the second-largest company by market capitalization on the KOSDAQ. With ongoing research and development efforts, Alteogen aims to advance into a leading global biopharmaceutical enterprise.

NexP™ Fusion Technology – Next generation persistent technology which utilizes human A1AT (ALPHA-1 Anti-trypsin) protein, abundant in human blood, as the protein carrier which increases half-life of biomedicines NexMab™ ADC Technology – Proprietary Antibody-Drug Conjugate (ADC) technology with superior stability, efficacy, and economical feasibility Hybrozyme™ Technology – Novel human hyaluronidase PH20 variant for subcutaneous (SC) drug delivery conversion from IV injection with improved thermal stability Biosimilars – Differentiated biosimilars with proprietary technology

Public

Biotech, CDMO, R&D Service